2023
A Randomized Trial of Three Routes of Tranexamic Acid Administration in Total Knee Arthroplasty.
Hootsmans N, Vellanky S, Grady-Benson J, Cremins M. A Randomized Trial of Three Routes of Tranexamic Acid Administration in Total Knee Arthroplasty. Orthopedics 2023, 46: 285-290. PMID: 36853950, DOI: 10.3928/01477447-20230224-04.Peer-Reviewed Original ResearchConceptsOral tranexamic acidTotal knee arthroplastyTopical TXA groupBlood transfusion rateTranexamic acidRoute of administrationTransfusion rateBlood lossChi-square testTXA administrationTXA groupKnee arthroplastyHemoglobin lossExact testPrimary total knee arthroplastySimilar clinical benefitsTranexamic acid administrationCalculated blood lossPearson's chi-square testFisher's exact testEase of administrationPerioperative bleedingBlood transfusionPrimary outcomeRandomized study
2022
Derivation and Validation of a Brief Emergency Department-Based Prediction Tool for Posttraumatic Stress After Motor Vehicle Collision
Jones C, An X, Ji Y, Liu M, Zeng D, House S, Beaudoin F, Stevens J, Neylan T, Clifford G, Jovanovic T, Linnstaedt S, Germine L, Bollen K, Rauch S, Haran J, Storrow A, Lewandowski C, Musey P, Hendry P, Sheikh S, Punches B, Lyons M, Kurz M, Swor R, McGrath M, Hudak L, Pascual J, Seamon M, Datner E, Harris E, Chang A, Pearson C, Peak D, Merchant R, Domeier R, Rathlev N, O'Neil B, Sergot P, Sanchez L, Bruce S, Miller M, Pietrzak R, Joormann J, Barch D, Pizzagalli D, Sheridan J, Smoller J, Harte S, Elliott J, Koenen K, Ressler K, Kessler R, McLean S. Derivation and Validation of a Brief Emergency Department-Based Prediction Tool for Posttraumatic Stress After Motor Vehicle Collision. Annals Of Emergency Medicine 2022, 81: 249-261. PMID: 36328855, PMCID: PMC11181458, DOI: 10.1016/j.annemergmed.2022.08.011.Peer-Reviewed Original ResearchConceptsMotor vehicle collisionsPosttraumatic stress symptomsValidation cohortSubstantial posttraumatic stress symptomsStress symptomsVehicle collisionsRisk-stratify individualsClinical decision support toolEmergency department patientsPersistent posttraumatic stress symptomsPreventive intervention trialNumber of EDsEase of administrationDerivation cohortPrimary outcomeDepartment patientsIntervention trialsBaseline healthHigh riskSymptomsCohortExternal validationPsychological recoveryDiscriminative abilityPosttraumatic stress“It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes
Hughes A, Chapman K, Bispham J, Dimsits J, Weinzimer S, Wolf W, Heydarian N. “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes. Journal Of Clinical & Translational Endocrinology 2022, 30: 100310. PMID: 36620758, PMCID: PMC9816066, DOI: 10.1016/j.jcte.2022.100310.Peer-Reviewed Original ResearchSevere hypoglycemiaType 1 diabetesGlucagon useMini-dose glucagonEase of administrationPrescription costsNasal administrationEmergency treatmentGlucagon actionPerspectives of adultsHypoglycemiaDiabetesGlucagon treatmentHealthcare professionalsGlucagonAverage durationPerspectives of peopleAdministrationAdultsParticipantsFocus groupsTreatmentCurrent studyFocus group interviewsEmotional impactA Flavonoid Compound 7, 4 Dihydroxy Flavone as a Potential Therapeutic for the Treatment and Management of EoE
Maskey A, Wang Z, Chen X, Dunkin D, Soffer G, Yuan Q, Li X. A Flavonoid Compound 7, 4 Dihydroxy Flavone as a Potential Therapeutic for the Treatment and Management of EoE. The FASEB Journal 2022, 36 DOI: 10.1096/fasebj.2022.36.s1.r4598.Peer-Reviewed Original ResearchLevels of TNFManagement of EoEIL-6Biopsy samplesAbnormal bowel movementsProlonged steroid useDihydroxy flavonesHigh relapse rateRisk of cancerAGE-RAGE pathwayHigh response rateSignificant reductionTraditional Chinese medicine practiceEase of administrationPathway analysisDietary eliminationOral steroidsSystemic steroidsAbdominal painBowel movementsEsophageal dysfunctionGI symptomsMaintenance therapyEosinophilic inflammationGastrointestinal reflux
2021
51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D
HUGHES A, CHAPMAN K, BISPHAM J, HEYDARIAN N, DIMSITS J, WEINZIMER S, WOLF W. 51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D. Diabetes 2021, 70 DOI: 10.2337/db21-51-lb.Peer-Reviewed Original ResearchSevere hypoglycemiaGlucagon useMini-dose glucagonUse of glucagonSevere hypoglycemic eventsEase of administrationOvernight hypoglycemiaGlycemic targetsHypoglycemia unawarenessHypoglycemic eventsPrescription costsSleep disruptorsTreatment decisionsNasal administrationHypoglycemiaDiabetes managementFocus groupsGlucagon actionGlucagon treatmentGlucagonEmotional impactAverage durationT1DPerspectives of peopleSpeakers bureau
2011
Vasoconstrictor Therapy for Hepatorenal Syndrome
Yeo C, Garcia-Tsao G. Vasoconstrictor Therapy for Hepatorenal Syndrome. Frontiers Of Gastrointestinal Research 2011, 28: 149-162. DOI: 10.1159/000318997.Peer-Reviewed Original ResearchHepatorenal syndromeReceptor agonistClinical trialsEffective arterial blood volumeType 2 hepatorenal syndromeAlpha-adrenergic receptor agonistIschemic adverse eventsNeurohormonal system activationPreferred alternative therapyRenal function effectsFirst-line therapyMain pathogenic mechanismRandomized clinical trialsAdrenergic receptor agonistArterial blood volumeVasopressin receptor agonistSuboptimal study designEase of administrationOral midodrineRenal vasoconstrictionSystemic vasodilatationVasoconstrictor therapyDefinitive therapyIntravenous albuminKidney injury
2001
Quality of Informed Consent: a New Measure of Understanding Among Research Subjects
Joffe S, Cook E, Cleary P, Clark J, Weeks J. Quality of Informed Consent: a New Measure of Understanding Among Research Subjects. Journal Of The National Cancer Institute 2001, 93: 139-147. PMID: 11208884, DOI: 10.1093/jnci/93.2.139.Peer-Reviewed Original Research
1998
Low molecular weight heparins: current use and indications
Quader M, Stump L, Sumpio B. Low molecular weight heparins: current use and indications. Journal Of The American College Of Surgeons 1998, 187: 641-658. PMID: 9849742, DOI: 10.1016/s1072-7515(98)00255-5.Peer-Reviewed Original ResearchConceptsUnfractionated heparinPrimary prophylaxisHeart diseaseSurgical proceduresIschemic heart diseaseValvular heart diseaseTreatment of patientsGeneral surgical proceduresAttention of cliniciansOrthopedic surgical proceduresEase of administrationSecondary prophylaxisPostoperative patientsPulmonary embolismThromboembolic complicationsUnstable anginaPredictable anticoagulationSignificant morbidityThromboembolic diseaseOutpatient settingMultiple traumaClinical trialsVascular surgerySimilar complicationsLMWHs
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply